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The cancer genome is highly complex, with hundreds
of point mutations, translocations, and chromosome
gains and losses per tumor. To understand the effects
of these alterations, precise models are needed.
Traditional approaches to the construction of mouse
models are time-consuming and laborious, requiring
manipulation of embryonic stem cells and multiple
steps. The recent development of the clustered regularly
interspersed short palindromic repeats (CRISPR)-Cas9
system, a powerful genome-editing tool for efficient
and precise genome engineering in cultured
mammalian cells and animals, is transforming mouse-
model generation. Here, we review how CRISPR-Cas9
has been used to create germline and somatic mouse
models with point mutations, deletions and complex
chromosomal rearrangements. We highlight the
progress and challenges of such approaches, and
how these models can be used to understand the
evolution and progression of individual tumors and
identify new strategies for cancer treatment. The
generation of precision cancer mouse models through
genome editing will provide a rapid avenue for
functional cancer genomics and pave the way for
precision cancer medicine.no established ES cell lines, which limits the studiesThe need for precision cancer models
The complexity of the cancer genome [1, 2] vastly ex-
ceeds the textbook view of a homogeneous mass of cells
with a handful of genetic mutations. A recent genomic
study using 4724 tumor-normal pairs across 21 cancer
types showed that each tumor-normal pair has, on aver-
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and tumor suppressor genes, precise modification of
genomic DNA will be needed to produce mutations that
can be carefully examined [1, 2, 4]. This will be particu-
larly important for the validation of the large numbers
of candidate cancer genes identified by The Cancer
Genome Atlas (TCGA) at the US National Institutes of
Health (NIH). TCGA aims to comprehensively characterize
the mutational landscape and genomic features of cancer.
Because a subset of mutations in cancer are not relevant to
cancer progression (so-called ‘passenger genes’), it is
important to functionally validate candidate genes to
identify those that are relevant to cancer progression
(‘cancer driver genes’). In the face of such a complex
genomic landscape, there is a need for simple and flex-
ible genetic methods to generate mouse models that
can identify functional cancer driver genes among the
vast number of passenger mutations.
Traditional cancer mouse models mostly rely on gen-
etically engineered transgenes or homologous recombin-
ation in embryonic stem (ES) cells [5]. By injecting
genetically modified ES cells into wild-type blastocysts,
chimeric animals with altered germlines are generated;
this is a costly and time-consuming way to produce
single-gene knockout mice or double-mutant mice.
Moreover, for most other mammalian species, there are
that can be undertaken in many species [5, 6]. As the
field moved towards more precise genome editing,
programmable nucleases, including zinc-finger nucle-
ases (ZFNs) and transcription-activator-like effector
nucleases (TALENs) [7], have been developed. These ap-
proaches have had some success; for example, a ZFN-
based approach for the HIV co-receptor gene CCR5 is in
clinical trials. However, both ZFNs and TALENs are
nuclease-based designs that are difficult to construct, and
the efficiency of targeting varies substantially, making
these laborious approaches.
Recently, the CRISPR-Cas9 system has transformed
genome editing (Fig. 1). CRISPR-Cas9 is an RNA-guidedle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Applications of CRISPR/genome editing for precision cancer models. CRISPR has been used to generate genetically modified mouse
models such as KO/KI germline models, somatic genome editing models and mouse models for drug treatment. CRISPR has been proved a
useful tool to investigate chromosomal engineering, generate ex vivo leukemia models and identify drug resistance genes through genome
editing of cell lines. CRISPR has also been used to correct disease-associated genes through homology-directed repair pathway. In combination
with traditional Cre-LoxP system, CRISPR can generate conditional KO/KI mouse models and further the understanding of cancer progression.
KO, knockout; KI, knock-in; sgRNA, single guide RNA
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archaea [4, 8–10] (Fig. 2a and Box 1). Cas9 is guided by
programmable RNA known as the single guide RNA
(sgRNA) [11–15]. The Cas9/sgRNA complex recognizes
the complementary 20-nucleotide genomic sequence
with a downstream protospacer-adjacent motif (PAM)Fig. 2 CRISPR-Cas9 mechanism. a A single guide RNA (sgRNA) is a fusion b
RNA). This complex recognizes the protospacer-adjacent motif (PAM) sequen
Cas9 cuts approximately three nucleotides upstream of the PAM to induce D
non-homologous end joining (NHEJ) or homology-directed repair (HDR), resu
bacteria recognize different PAM sequences; S. pyogenes Cas9 recognizes ‘NG
CRISPR-Cas approaches. b sgRNA targeting tumor suppressor genes can lead
can be used to introduce precise genome editing through HDR (for examplesequence (Fig. 2a). Cas9 proteins from different bacteria
recognize different PAM sequences; for example,
Streptococcus pyogenes Cas9 recognizes the ‘NGG’ PAM
and the weaker ‘NAG’ PAM sequences [16]. Because
most studies use S. pyogenes Cas9 as a genome-editing
tool, we will use ‘CRISPR-Cas9’ to represent this Cas9etween crRNA (CRISPR RNA) and tracrRNA (trans-activating CRISPR
ce and the complementary 20-nucleotide upstream genomic sequence.
NA double-strand breaks. Then, the cellular DNA repair system, either
lts in indels or precise editing, respectively. Cas9 proteins from different
G’ PAM and the weaker ‘NAG’ PAM. b, c Key underlying principles for
to loss-of-function frameshift mutations through NHEJ. c Template DNA
, oncogene mutations). Dashed lines denote homologous recombination
Box 1 Factors to consider when choosing a CRISPR
approach
1. Predict top-ranking single guide RNAs (sgRNAs) using published
tools such as CRISPR Design Tool [16], sgRNA Designer [79],
E-CRISP [80], via the Cas-OFFinder [81] or CRISPRseek [82].
2. Clone sgRNA into pX330 vector [16] for transient expression
or improved lentivectors [83] for stable expression.
3. Several groups have reported being able to increase genome-
editing efficiency by microhomology-based choice of target
sites [84,85] or by rational design of homology-directed repair
(HDR) templates [86] and small molecular compounds [87,88].
4. A detailed protocol for generating a germline CRISPR mouse
model was recently published [26].
5. For in vitro CRISPR, choose one sgRNA to introduce indels
mediated by non-homology end joining (NHEJ) or precise point
mutations mediated by HDR in the presence of template DNA
in order to investigate a single gene knockout and establish
genetically modified cell lines. For multiple gene modifications,
multiple sgRNAs can be used to disrupt multiple genes.
6. Adenovirus, adeno-associated virus (AAV) and lentivirus can
be used to deliver CRISPR in vivo to establish cancer mouse
models [24], depending on the efficiency of infected tissues.
7. Two sgRNAs to generate two double-strand DNA breaks in
the chromosomal regions of interest can be used to model
large chromosomal deletions, inversions and translocations. A
combination of Cre-LoxP and CRISPR can introduce additional
genetic modification in available Cre-LoxP knockout or knock-in
mouse models.
8. dCas9 without catalytic function fused with regulatory
domains [89–94] and chimerical sgRNA scaffold [95,96] can be
used in gene regulation studies.
9. Finally, CRISPR can be used for genome-wide screens to identify
drug target genes or resistant genes using sgRNA libraries. This
genome-wide screening strategy can also be adapted to identify
novel tumor suppressor genes or oncogenes if properly designed.
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stream of the PAM sequence to induce double-strand
DNA breaks (DSBs). These breaks are then repaired by
the cells’ DNA damage repair mechanisms using either
the error-prone non-homologous end-joining (NHEJ)
pathway, which gives rise to small insertions and dele-
tions (indels) (Fig. 2b), or the homology-directed repair
(HDR) pathway that, in the presence of a donor double-
stranded or single-stranded DNA, can lead to precise
DNA modification (Fig. 2c).
CRISPR-Cas9 genome editing has made it easy, fast
and effective to build precision cancer models. It hasalready been used to generate knockout or knock-in
mouse models in ES cells and zygotes [17, 18]. In vivo
delivery of CRISPR has been used to correct disease
genes in mouse liver [19], and the CRISPR technique
has been used to engineer structural variations, such as
translocations, deletions and inversions [20–23]. It has
also shown promise as a tool for modeling cooperative
genetic events in lung cancer [24, 25], performing genome-
scale screening [24, 25], and studying transcription regula-
tion [26, 27] via catalytically deactivated Cas9 (dCas9).
CRISPR-Cas9 is a rapid and flexible system that has the
potential to speed up building of precision mouse models.
Here, we summarize the recent innovations that have
permitted multiple applications of the CRISPR genome-
editing system for building precision cancer mouse
models and their implications for advancing cancer biol-
ogy (Table 1). We will highlight a broad range of cancer-
specific approaches to CRISPR gene-editing and discuss
the efficacy of such approaches for generating cancer
mouse models and how they can be used to further the
understanding of tumor biology.
Generating mouse models using the CRISPR system
The CRISPR system can be used to induce genetic muta-
tions in as little as 4 weeks [26] and provides a flexible
platform for functional annotation of the cancer gen-
ome. The general principles of applying the CRISPR-
Cas9 system are as follows. First, an sgRNA harboring a
20-nucleotide genomic sequence from a gene of interest
needs to be designed, and second, NHEJ or HDR is used
to introduce indels or precise repair, respectively (Fig. 2,
Box 1). Of note, HDR efficiency is usually low and sev-
eral studies have demonstrated methods to increase
HDR efficiency by inhibiting NHEJ enzymes [27]. The
system can be customized for specific projects, mainly
through design of the sgRNA strand. For example, an
sgRNA that targets a protein-coding region can produce
loss-of-function frameshift indel mutations through
NHEJ (Fig. 2b) and sgRNA/template DNA can introduce
precise genome editing through HDR (Fig. 2c). Cur-
rently, two complementary approaches, germline and
somatic, are being used to build mouse models via gen-
ome editing.
Germline CRISPR mouse models
Germline mouse models are developed by introducing
cancer mutations into mouse ES cells or developing em-
bryos. This method can generate germline-transmittable
genetic alleles, allowing maintenance and breeding of the
established alleles through mouse husbandry. CRISPR-
Cas9 can precisely introduce DSBs in a one-cell-stage em-
bryo, accelerating the generation of genetically modified
mice as this stage is no longer dependent on the generation
of suitable ES cells [26, 28]. For example, mice carrying a
Table 1 List of CRISPR-generated animal models useful for the study of oncology and disease
Animal Vehicle for delivery Target tissue Delivery Genes targeted Utility Reference
Germline Mouse mRNA, sgRNA and
donor DNA
Embryo One-cell embryo injection Nanog, Sox2, Oct4 Generation of
reporter genes
[18]
Mouse mRNA, sgRNA and
donor DNA
Embryo One-cell embryo injection Mecp2 Cre-LoxP
conditional mutant
Rett syndrome [18]
Mouse mRNA and sgRNA Embryo One-cell embryo injection Tet1 and Tet2 and
others
Epistatic gene
interactions
[17]
Rat mRNA and sgRNA Embryo One-cell embryo injection * ** [29]
Cynomolgus
monkey
mRNA and sgRNA Embryo One-cell embryo injection Pparg and Rag1 ** [30]
Mouse Plasmid DNA ES cell Dox-inducible Cas9 alleles p53, Apc, Pten Colon cancer [36]
Somatic Mouse Plasmid DNA Liver Hydrodynamic injection Pten, p53 and β-
catenin
Hepatocellular
cancer
[25]
Mouse Adenovirus Liver Intravenous injection Pcsk9 Cardiovascular
disease
[32]
Mouse Adenovirus Liver Intravenous injection Cebpa Liver function [33]
Mouse AAV Brain Stereotactic delivery Mecp2 Rett syndrome [34]
Mouse AAV Brain Stereotactic delivery Dnmt1, Dnmt3a
and Dnmt3b
Learning/memory [34]
Mouse AAV Brain Stereotactic injection NeuN (Rbfox3) ** [35]
Mouse sgRNA in nanoparticle Pulmonary/
cardiovascular
Intravenous injection Icam2 ** [35]
Mouse AAV, AAV donor
template
Lung Intranasal/intratrachael
delivery
p53 and Lkb1, Kras Non-small-cell
lung cancer
[35]
Mouse Lentivirus Lung Intratracheal delivery Nkx2.1, Pten, Apc Non-small-cell
lung cancer
[24]
Mouse Adenovirus Lentivirus Lung Intratracheal delivery Eml4-Alk Non-small cell
lung cancer
[22, 39]
Lymphoma Mouse Lentivirus HSPCs ex vivo Intravenous injection of
Cas9-edited human HSPCs
TET2, DNMT3A,
RUNX1, NF1, EZH2
AML [41]
Mouse DNA electroporation Fetal-liver
HSCs ex vivo
Intravenous injection of
Cas9-edited HSCs
Mll3 AML [43]
Mouse Lentivirus Fetal-liver
HSCs ex vivo
Intravenous injection of
Cas9-edited HSCs
Mcl-1, p53 Dox-inducible
Burkitt lymphoma
model
[44]
Mouse Retrovirus Lymphoma
cells ex vivo
Intravenous injection of
Cas9-edited mouse
Arf−/−; Eμ-myc cells
p53 Role of p53 in
chemotherapy
resistance
[42]
*Paper reports on protocol for rat-specific editing, does not investigate targeting of specific genes. **Applications of model for study of disease not critical focus
of experiment. Donor DNA used as template for homologous recombination. AAV, adeno-associated virus; AML, acute myelogenous leukemia; Dox, doxycycline;
ES cell, embryonic stem cell; HSPC, hematopoietic stem and progenitor cell; HSC, hematopoietic stem cell; sgRNA, single guide RNA
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Oct4 (important stem cell genes) as well as a Mecp2 condi-
tional mutation (a Rett syndrome gene) were generated by
one-step co-injection of zygotes with Cas9 mRNA, differ-
ent sgRNAs and DNA vectors (Fig. 3a) [18].
Moreover, CRISPR germline editing has been used to
generate mice with biallelic mutations in the epigenetic
genesTet1 and Tet2 by one-step co-injection of Cas9
mRNA and sgRNAs [15]. It has also been used to sim-
ultaneously disrupt five genes (Tet1, 2, 3 and Sry, Uty-
8 alleles) in mouse ES cells [17]. Furthermore, CRISPR
was used to generate precise point mutations in twotargeted genes simultaneously in the presence of
single-stranded DNA oligonucleotides with point mu-
tations as templates for HDR repair. This is a useful
approach for exploring redundant genes and epistatic
gene interactions in vivo [17]. Of note, this one-step
CRISPR injection system has also been used to pre-
cisely target genes in rat [29] and cynomolgus monkey
[30] one-cell embryos.
Somatic CRISPR mouse models
Most non-familial cancer is caused by the accumulation
of genetic mutations in somatic cells. Somatic mouse
Fig. 3 Rapid generation of cancer models in mouse through genome editing. a Germline CRISPR mouse models. Cas9 and single guide RNA
(sgRNA) can be microinjected into mouse zygotes. The resulting mouse will carry cells harboring CRISPR-mediated indels or homology-directed
repair. This method can generate mosaic mice. b Somatic CRISPR mouse models. Cas9 and sgRNA can be delivered to mouse tissue in vivo, for
example through hydrodynamic injection to the liver or viral vehicles to various tissue. c Two sgRNAs targeting one chromosome can lead to
deletion or inversion between sgRNA cutting sites. d Two sgRNAs targeting two chromosomes can lead to chromosomal translocation, allowing
rapid modeling of cancer-associated chromosomal rearrangement. Chr, chromosome
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progression and bypass the embryonic lethality caused
by whole-body knockout of certain genes. The large size
of Cas9 (4 kilobases (kb)) is a challenge for delivery to
somatic cells in mice. However, several plasmid delivery
approaches (mainly to the liver because it is the most
amenable organ to DNA delivery) and viral delivery ap-
proaches for CRISPR-Cas9 have been applied to generate
somatic mouse models of cancer.
Hydrodynamic injection is a well-established method
of delivering plasmids selectively to the liver in animal
models. This method uses high-volume/high-pressure
tail-vein injection to transiently express DNA in 20 to
30 % of mouse hepatocytes. For example, DNA plasmids
encoding Cas9 and sgRNAs were delivered to the liver
to target the tumor suppressor genes Pten and p53,
alone or in combination (Fig. 3b) [25]. Strikingly, when
Pten was mutated by CRISPR in hepatocytes, two liver
phenotypes were observed: elevated Akt phosphorylation
and lipid accumulation. Furthermore, simultaneous disrup-
tion of Pten and p53 induced tumor formation, phenoco-
pying the effects of deletion of the genes using Cre-LoxP
technology [25]. The feasibility of inducing point mutations
in tumor suppressor genes and oncogenes in the liver
was also demonstrated by co-injection of Cas9-sgRNA
plasmids targeting β-catenin and a single-stranded
DNA oligonucleotide donor carrying activating point
mutations, resulting in hepatocytes with activation of
β-catenin localizing in the nucleus [25]. Notably, a
similar TALEN approach has been used to edit the β-
catenin gene in mouse liver [31]. These advances inrapidly modeling liver cancer pave a new way for stud-
ies of functional cancer genomics.
In addition to plasmid-based delivery and TALEN-
based approaches, various virus-based approaches have
been developed to increase delivery efficiency and target
organs other than the liver. For example, an adenovirus-
based CRISPR-Cas9 expression system was used to
introduce loss-of-function mutations in the endogenous
Pcsk9 gene, and resulted in decreased plasma Pcsk9
levels, increased hepatic low-density lipoprotein receptor
levels and decreased plasma cholesterol levels, all of
which are well known to be regulated by Pcsk9 [32]. An-
other group reported using adeno Cas9n (Cas9D10A nick-
ase capable of cutting only one DNA strand compared
with wild-type Cas9, which can cut both strands, usually
used to avoid off-target effects)-based delivery of CRISPR
to mouse liver for disruption of Cebpa, a well-known
metabolic transcription factor, and found a downstream
molecule expression pattern similar to liver-specific Cebpa
knockouts [33].
A Cas9/sgRNA delivery vector based on adeno-
associated virus (AAV), with its non-pathogenic, potent
and simple-to-engineer capability, has been used to tar-
get post-mitotic neurons in adult mice to elucidate the
genetics of complex disorders that affect cognition and
behavior. AAV vectors expressing Cas9 and sgRNA tar-
geting a single gene (Mecp2, which causes the neurode-
velopmental disorder Rett syndrome), as well as multiple
genes (Dnmt1, Dnmt3a and Dnmt3b from the DNA
methyltransferase family), in adult mouse brains have
been stereotactically injected into the dentate gyrus,
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brain [34]. This technique provides a potentially applic-
able method to model brain cancer by multiplex disrup-
tion of candidate genes.
A challenge in the field of CRISPR-based genome en-
gineering is the delivery of the Cas9 endonuclease, which
is large (4 kb). In an attempt to tackle this shortcoming,
a Cre-dependent Cas9 knock-in mouse was generated
and used for in vivo as well as ex vivo genome editing
[35]. Using this system, a single AAV vector was deliv-
ered in the lung to generate loss-of-function mutations
in p53, and Lkb1 as well as HDR-mediated KrasG12D mu-
tations, which phenocopied the pathology of lung adeno-
carcinoma [35]. The Cas9 mouse provides a simplified
model for somatic genome editing by expressing Cas9 in
the germline, allowing constitutive and Cre-inducible
Cas9 expression in organs of interest. Similarly, Lowe
and colleagues [36] described the use of doxycycline-
inducible Cas9 and Cas9D10A mouse models to perform
inducible genome editing in mice.
Cancer-specific applications of CRISPR-Cas9
Recent cancer genome projects have identified a pleth-
ora of genomic alterations, such as deletions, inversions
and translocations [3]. However, creating large structural
variations using Cre-LoxP methods is time-consuming
and therefore the function of many cancer-associated
structural variations is not known. In addition, to fully
explore cancer in a mouse model, it is necessary to look
beyond solid tumors to leukemia models. In the past few
months, several groups have demonstrated the potential
of the CRISPR-Cas9 system for engineering large
chromosomal changes and for ex vivo engineering.
Engineering structural variations
Cell-line, ES-cell and somatic approaches have all
been used to generate cancer- or disease-associated
structural variations. For example, the engineering of
CRISPR-mediated genomic deletions ranging from
1.3 kb to greater than 1 megabase (Mb) in mammalian
cells has been reported and an inverse relationship ex-
ists between deletion frequency and deletion size [37].
Two sgRNAs that target one chromosome can lead to
deletion or inversion between sgRNA cutting sites
(Fig. 3c). Two sgRNAs targeting two chromosomes can
lead to chromosomal translocation (Fig. 3d). These tech-
niques allow rapid modeling of cancer-associated chromo-
somal rearrangement.
Chromosomal rearrangements, including CD74-ROS1
translocation events and the EML4-ALK and KIF5B-RET
inversion events, occur in lung cancer patients. These
rearrangements have been generated by CRISPR-Cas9
technology [20, 38]. In addition, chromosomal transloca-
tions between the EWSR1 and FLI1 loci and between theAML1 (also known as RUNX1) and ETO (also known as
RUNX1T1) loci, which are involved in Ewing’s sarcoma
and acute myeloid leukemia (AML), respectively, have
been generated by CRISPR in human cell lines [23]. This
provides an effective method to reproduce precise recip-
rocal tumor-associated chromosomal translocations to
better understand the initiation of leukemia and sar-
coma. Recently, Kraft and colleagues [21] reported that
they had rearranged targeted genomic intervals from
1 kb to 1.6 Mb using the CRISPR-Cas9 system at six dif-
ferent loci associated with human disease, comprising
H2afy, Bmp2, Ihh, Pitx1, Laf4 (also known as Aff3) and
Epha4. They observed deletions and inversions at all
sites, and duplications in Pitx1 and Laf4 with 0.7 % and
28.1 % frequency, respectively. The deletion of 353 kb
and 1.6 Mb genomic intervals at the Laf4 and Epha4 loci
recapitulated human malformation syndromes and
neurological phenotypes [21]. This study suggests that
CRISPR can be used to genetically modify multiple
genes from different loci and large genomic regions. The
same strategy can be applied to mouse cancer models
since cancer involves complex structural variants.
In addition to modeling chromosomal rearrangements
in cell lines and ES cells, viral delivery of the CRISPR-
Cas9 system to generate the Eml4-Alk rearrangement in
non-small-cell lung cancers (NSCLCs) [22, 39] has been
reported in mouse models. Our groups have recently
shown that hydrodynamic injection of two sgRNAs led
to deletion and inversion of a 50 kb Pten genomic region
in mouse liver [40]. Together, these studies demonstrate
that CRISPR is a feasible method to generate chromo-
somal rearrangements in vivo.Leukemia models
In addition to somatic genome engineering in vivo, sev-
eral groups have reported efficient ex vivo engineering
of hematopoietic stem cells (HSCs). HSCs are trans-
duced with CRISPR-Cas9 viral vectors in vitro and
transplanted into recipient mice, allowing for rapid
generation of novel mouse models of hematopoietic
malignancies [41–44]. For example, a recent report
demonstrated efficient modification of up to five genes
by delivering combinations of sgRNAs and Cas9 with a
lentiviral vector in HSCs [41]. This led to clonal out-
growth and myeloid malignancy, thus generating models
of AML. This study suggests that lentivirus-delivered
sgRNA-Cas9 genome editing is another useful tool to en-
gineer hematopoietic cancer models [41].
The above studies demonstrated that CRISPR can be
used to engineer structural variants such as insertions,
deletions, mutations and translocations, as well as to
model leukemia. These advances pave the road to gener-
ating more complex cancer models.
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Cancer involves a complex combination of mutations in
tumor suppressor genes and oncogenes. Cancer genome
sequencing studies have identified a variety of genetic al-
terations. However, not all the alterations contribute to
tumorigenesis. Distinguishing cancer driver genes from
passenger genes is a major challenge for cancer research.
Recent studies have demonstrated the power of
combining the CRISPR-Cas9 system with well-studied
conditional mouse models of cancer. Notably, a som-
atic genome engineering approach that combines Cre-
dependent somatic activation of KrasG12D [45–47]
with CRISPR-Cas9-mediated genome editing of tumor
suppressor genes has been shown to enable the rapid
functional characterization of putative lung cancer
genes using mouse models [24]. In this study, a
pSECC lentiviral system was used to deliver both the
CRISPR system and Cre recombinase, thus allowing
for the examination of CRISPR-meditated mutations
of genes in the context of well-studied Cre-LoxP lung
cancer models. For instance, it was demonstrated that
in KrasLSL-G12D/+ and KrasLSL-G12D/+; p53fl/fl lung
tumor models, loss of NK2 homeobox1 (Nkx2-1) [48]
or Pten accelerated tumorigenesis [24]. Furthermore,
this system has also been used to characterize the
functional role of a novel lung tumor suppressor gene,
adenomatous polyposis coli (Apc) [24]. Thus, combin-
ing CRISPR and Cre-LoxP models bypasses the la-
borious breeding of mouse alleles and significantly
accelerates the pace of generation of complex mouse
models.
The heterogeneity of tumor cells makes it difficult to
trace which populations of cells eventually progress to
malignancy and gain the ability to aggressively migrate
and invade [49]. Because CRISPR induces indels at target
genes in tumor cells [24, 25], we may be able to use
these indels as ‘molecular barcodes’ to trace single-cell
lineages and investigate the contribution of different
populations of tumor cells to tumorigenesis and progres-
sion. For example, sgRNA targeting Pten has been
shown to introduce diverse indels such as a ‘+C’ inser-
tion and ‘-A’ and ‘-AA’ deletions at the sgRNA target site
[25]. These indels could potentially serve as ‘DNA bar-
codes’ to differentiate tumor cell clones harboring
unique CRISPR-induced indels.
Precision models for cancer treatment and
resistance
Besides building various cancer models, the CRISPR-
Cas9 system can also be used to explore drug treatment
and resistance. In an Arf−/− Eμ-myc B-cell lymphoma
mouse model, CRISPR-Cas9-mediated disruption of p53
confers cells with resistance to doxorubicin treatment
[42]. A new mouse model of Eml4-Alk-driven lung cancerengineered by CRISPR-mediated oncogenic chromosomal
rearrangements has shown marked sensitivity to the Alk-
inhibitor crizotinib [22]. These CRISPR mouse models
provide a useful tool for exploring drug treatment and po-
tential drug-sensitive or drug-resistant genes to advance
therapeutic strategies for cancer patients (Fig. 4a).
Several groups have reported the successful implemen-
tation of the CRISPR-Cas9 system for large-scale high-
throughput genetic screens. A pooled loss-of-function
genetic screening approach has been described [50, 51].
In one study, a genome-scale lentiviral sgRNA library
was used to generate knockout pools of cells and per-
form screens [51]. sgRNAs targeting a drug target gene
essential for cell survival were depleted in the cell popu-
lation. An sgRNA library targeting the BCR and ABL1
genes was used to screen sgRNAs targeting the BCR-
ABL fusion protein, which is the drug target of Gleevec,
used to treat chronic myelogenous leukemia (CML) [51].
sgRNAs targeting the exons of the BCR and ABL1 fusion
genes were depleted in the screen, confirming that the
BCR-ABL fusion protein is required for the survival of
CML cells. This study suggests that CRISPR can be used
to knockout candidate genes, accelerating the identifica-
tion of novel drug target genes.
As mentioned above, CRISPR screens have been estab-
lished to identify drug resistance genes on a genome-wide
scale. For example, lentiviral delivery of a genome-wide
CRISPR-Cas9 knockout library targeting 18,080 genes
with 64,751 unique guide sequences enables both negative
and positive selection screening in human cells [50]. This
system has been used to screen for genes involved in
resistance to vemurafenib, a therapeutic inhibitor of the
oncogenic BRAF protein. The screening yielded high-
ranking candidate genes that include previously vali-
dated genes such as NF1 and MED12 as well as novel
hits NF2, CUL3,TADA2B and TADA1 [50, 51]. Using
the same CRISPR library screening method, two studies
reported screens for resistance to the nucleotide analog
6-thioguanine and identified all the members of the
DNA mismatch repair pathway, demonstrating that
CRISPR genome-wide screening is a reliable approach
to identify novel drug resistant genes and pathways
(Fig. 4b) [51, 52].
Precise genome editing also holds great promise for
correcting genetic disease genes [53]. We have shown
that in vivo delivery of CRISPR components can correct
the hereditary tyrosinemia gene Fah in the adult mouse
liver [19] (Fig. 4c). Several groups have also demon-
strated correction of genetic disease genes, such as the
cystic fibrosis transmembrane conductance regulator
(CFTR) gene in intestinal organoids [54], a dominant
mutation in the Crygc gene that causes cataracts [55],
and the Duchenne muscular dystrophy (Dmd) gene in
mouse zygotes [56].
Fig. 4 Precision models for cancer drug treatment and resistance. a CRISPR-induced gene knockout or engineered drug target alleles (for example,
EML-ALK) can be used for testing drug sensitivity or resistance in cultured cells or mice. b A lentiviral single guide RNA (sgRNA) library can be stably
introduced into cells through pooled infection. Deep sequencing will measure sgRNA enrichment or depletion upon drug treatment to identify
drug-resistant or drug-sensitive genes. c A diagram of genetic disease correction (adapted from [19]). A homology-directed repair (HDR) template
single-stranded DNA carrying a wild-type ‘G’ nucleotide was applied to repair the ‘A’ mutation in the last position of exon 8 in the type I tyrosinemia
gene Fah
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Despite tremendous progress in the past 2 years with the
CRISPR-Cas9 system and the generation of cancer models,
a few challenges still remain. The major remaining obstacle
is the delivery of Cas9 for building somatic mouse models
and for using CRISPR-Cas9 to correct disease gene muta-
tions in vivo. Improved CRISPR delivery (protein [57, 58]
or mRNA) and split Cas9 [59, 60] will enhance the effi-
ciency of in vivo genome editing. Finding alternative Cas9
proteins with smaller sizes [61–63] will also facilitate
CRISPR viral vector packaging.
In addition, although CRISPR-Cas9 has been demon-
strated as a flexible research tool, the safety of Cas9 re-
mains a concern for the scientific community [64].
Future work is required to carefully evaluate the safety
of CRISPR-Cas9.
Precision mouse models require minimal off-target ef-
fects. Several groups have developed technologies to re-
duce off-target genome editing, such as Cas9D10A
nickase and offset sgRNAs [65, 66], truncated sgRNA
[67, 68] and dCas9-FokI fusions [69]. Genome-wide ana-
lysis of Cas9 off-target sites has been reported [70–72].
Monitoring off-target effects will be an important part of
developing this method.Conclusions and future discussions
With the successful sequencing of human tumor genomes
by large-scale efforts, such as TCGA, functional studies
are required to conclusively identify novel bona fide tumor
suppressor genes or oncogenes. The CRISPR system pro-
vides a fast, easy and reliable method to establish cancer
models, explore drug treatments and identify various
novel drug target genes and resistance genes [73]. As can-
cer involves complex alterations and mutations of tumor
suppressor genes and oncogenes, CRISPR is a promising
way to establish and investigate cancer models. At the
same time, it will allow researchers to explore therapeutic
strategies inspired by CRISPR-based genetic screens [74].
CRISPR has been used to establish different cancer
mouse models using a variety of techniques. These in-
clude germline editing and somatic genome editing for
modeling gene knockouts, knock-ins and chromosomal
rearrangements. This has led to the creation of knockout
and knock-in mouse models, solid tumor models and
leukemia mouse models. The combination of CRISPR
with traditional Cre-LoxP methods shows promise in the
ongoing effort to establish precision mouse models to
better understand the cooperative effects of tumor sup-
pressor genes and oncogenes. CRISPR is also amenable
Mou et al. Genome Medicine  (2015) 7:53 Page 9 of 11for genome-wide screening to identify drug-resistant
genes. CRISPR-mediated genome editing and genetic
screens will facilitate cancer genomics and functional
studies.
In the future, the CRISPR-Cas9 system will be more
finely tuned, accelerating in vitro and in vivo genome
editing to establish novel cancer models and better
understand cooperative effects among complex tumor
suppressor gene and oncogene networks. Furthermore,
engineering new Cas9 fusion proteins with novel char-
acteristics, such as light-inducible dCas9 [75, 76],
could confer CRISPR with additional advantages. In
vivo CRISPR screens [77] may identify new cancer
driver genes in a similar fashion to in vivo RNA-
interference-based approaches [78]. Apart from refining
the CRISPR system, we may also be able to broaden the
application of CRISPR to gene therapy, from fixing single-
gene mutations to multiplex gene modifications to pre-
cisely edit the genome and eventually combat complex
genetic diseases such as cancer and diabetes. This novel
technology will continue to revolutionize modern biology.
Furthermore, we envision the use of genome-editing ap-
proaches for generating cancer mouse models to under-
stand the progression of individual tumors and to identify
treatment strategies. Precision cancer mouse models will
pave the road for precision cancer medicine.
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